Traws PharmaTRAW
TRAW
About: Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
Employees: 7
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
170% more capital invested
Capital invested by funds: $3.8M [Q3] → $10.2M (+$6.45M) [Q4]
73% more funds holding
Funds holding: 11 [Q3] → 19 (+8) [Q4]
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
3.31% more ownership
Funds ownership: 35.32% [Q3] → 38.63% (+3.31%) [Q4]
53% less call options, than puts
Call options by funds: $178K | Put options by funds: $376K
Research analyst outlook
We haven’t received any recent analyst ratings for TRAW.
Financial journalist opinion
Based on 5 articles about TRAW published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript
Traws Pharma, Inc. (NASDAQ:TRAW ) Virtual Investor Event March 31, 2025 10:00 AM ET Company Participants Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza – Chief Science Officer-Virology Iain Dukes – Executive Chairman Bruce Mackle – LifeSci Advisors Conference Call Participants Operator Good morning, and welcome to the Traws Pharma Investor Call on Bird Flu and COVID and Traws Innovative Small Molecule Product Candidates. At this time all attendees are in a listen-only mode.
Neutral
GlobeNewsWire
3 weeks ago
Traws Pharma Announces Management Updates
NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assume the role of Interim CEO. In addition to his new responsibilities, Dr. Dukes will continue to serve as Traws' Chairman.
Neutral
GlobeNewsWire
3 weeks ago
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird Flu Ratutrelvir, a main protease inhibitor, to be used without ritonavir, for COVID-19 NEWTON, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that it will host a virtual investor event on Monday, March 31, 2025 at 10:00 AM ET.
Neutral
GlobeNewsWire
3 weeks ago
Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR
NEWTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that positive data supporting the potential for ratutrelvir, a main protease inhibitor, as a treatment for COVID-19, were presented on March 20, 2025 in a poster at the International Conference for Antiviral Research (ICAR 2025), held in Las Vegas, Nevada.
Neutral
GlobeNewsWire
4 weeks ago
Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
NEWTOWN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that positive data supporting the potential for tivoxavir marboxil (TXM) as a bird flu treatment was presented yesterday in a poster at the International Society for Antiviral Research (ICAR 2025), being held in Las Vegas, Nevada.
Neutral
GlobeNewsWire
1 month ago
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline results from ferrets infected with H5N1 bird flu, an accepted animal model for human influenza, when treated with tivoxavir marboxil as a single dose. These data are consistent with results reported in December 2024 in a murine model. The new studies reported today evaluated the efficacy of a single dose of tivoxavir marboxil as a treatment for bird flu isolated from a Texas dairy worker and showed suppression of disease, with reduced viral burden in lungs.
Neutral
GlobeNewsWire
1 month ago
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
NEWTOWN, Pa., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for the treatment of respiratory viral diseases, announced today that it has received confirmation from Nasdaq that Traws has regained compliance with the minimum stockholders' equity requirements of Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2.5 million in stockholders' equity. Accordingly, Traws common stock will continue to be listed and trade on The NASDAQ Capital Market under the symbol “TRAW”.
Neutral
PRNewsWire
2 months ago
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention NEWTOWN, Pa. , Jan. 23, 2025 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced completion of Phase I clinical studies of its investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir), for the treatment or prevention of H5N1 bird flu.
Neutral
PRNewsWire
3 months ago
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
SAN DIEGO , Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (NASDAQ: TRAW) H5N1 antiviral program. The investigational drug, Tivoxavir Marboxil, has shown encouraging results as a single-dose treatment for H5N1 avian influenza, representing a potentially pivotal advance in addressing this serious health challenge.
Neutral
PRNewsWire
3 months ago
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term value inflecting readouts NEWTOWN, Pa. , Dec. 30, 2024 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases including bird flu, today announced that it has entered into definitive agreements to raise up to $72.6 million before deduction of placement agent's fees and other estimated offering expenses.
Charts implemented using Lightweight Charts™